Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of sotrovimab IV as primary prophylaxis in SARS-CoV-2 vaccine non-responders
2021-006495-16Phase 2Terminated
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 1 more. Started Dec 2021; status: terminated.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-006495-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006495-16.